Effects of tadalafil on hemorrhagic cystitis and testicular dysfunction induced by cyclophosphamide in rats.
BACKGROUND
The protective and/or therapeutic potential of tadalafil (TDL) on cyclophosphamide (CP)-induced hemorrhagic cystitis (HC) and testicular dysfunction in rats was evaluated.


METHODS
The animals except from the control group were divided into four groups and treated with saline, or 1, 5 or 10 mg/kg TDL orally (CP, TDL1, TDL5 and TDL10 groups, respectively) before and after CP injection. Body and organ weights, sperm count, cGMP, nitric oxide (NO), IL-6 and IL-10 levels in serum and bladder tissue, and serum testosterone (T), LH and FSH levels were determined. The histological analysis of bladder and testis was performed and the number of apoptotic cells was determined.


CONCLUSIONS
The CP group had decreased cGMP and NO levels in the bladder, serum T level (p < 0.05) and sperm count (p < 0.001) and higher IL-6 levels in serum and bladder (p < 0.01). Treatment with TDL resulted in increased cGMP (p < 0.001), NO (p < 0.05) and serum T (p < 0.05) levels. Histological analysis of the CP group showed severe HC in bladder and testicular damage. TDL-treated animals showed a dose-dependent improvement in all of these histological impairments. In conclusion, a selective inhibitor of phosphodiesterase-5 enzyme, TDL, showed a protective and/or therapeutic effect on CP-induced HC and testicular dysfunction in rats.
Department of Pharmacology, School of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.
Semra
S
Yigitaslan
Orhan
O
Ozatik
Fikriye Yasemin
FY
Ozatik
Kevser
K
Erol
Basar
B
Sirmagul
Ali Barbaros
AB
Baseskioglu
D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D001835:Body Weight; D002243:Carbolines / Q000627:therapeutic use*; D006152:Cyclic GMP / Q000378:metabolism; D003520:Cyclophosphamide / Q000009:adverse effects*; D003556:Cystitis / Q000188:drug therapy*; D005640:Follicle Stimulating Hormone / Q000097:blood; D007150:Immunohistochemistry; D016753:Interleukin-10 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009569:Nitric Oxide / Q000378:metabolism; D009929:Organ Size; D051381:Rats; D017207:Rats, Sprague-Dawley; D013076:Sperm Count; D000068581:Tadalafil; D013696:Temperature; D013737:Testis / Q000187:drug effects* / Q000473:pathology; D013739:Testosterone / Q000097:blood; D064804:Urological Agents / Q000627:therapeutic use
D000975:Antioxidants; D002243:Carbolines; D015850:Interleukin-6; D064804:Urological Agents; D016753:Interleukin-10; D009569:Nitric Oxide; D013739:Testosterone; D000068581:Tadalafil; D003520:Cyclophosphamide; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D006152:Cyclic GMP